学术报告会开场白和结束语 第1篇
竭诚为您提供优质文档/双击可除学术报告会英文主持词篇一：外国专家英文讲座主持稿(英汉对照)外国专家英文讲座主持稿（英汉对照）goodevening,ladiesandgentlemen！女士们先生们，大家晚上好！RTutori ngLectureseriesoftheIAhRwhusc, rheretoholdanDoctoralsupervisorForum,I’myourhostxxx.欢迎来到IAhR武汉大学学生分会“科学研究与论文写作辅导系列讲座”第4期活动现场，今天我们很高兴能够为大家举办一场博导论坛，我是主持人xxx。
erforRenewableenergy,-.今天我们非常有幸邀请到了prebenmaegaard来到武汉大学。
prebenmaegaard来自北欧可再生能源总中心，他是这个非政府机构的建立者和名誉主任。
R endtouschinese.他从1970年代就开始投身于新能源发展事业，为了表彰他的贡献，他被授予xxx，xxx和xxx等奖项。
学术报告会开场白和结束语 第2篇
英文学术会议开场的演讲稿SANY GROUP system office room 【SANYUA16H-Good morning, ladies and gentleman. Welcome to Xian, a beautiful city of China. I’m Xinpei Zhang. It is a great pleasure to participate in the Mathematics Conference as the chairman. And I really enjoy staying here with you this morning. The Mathematics Conference has been held 4th times by Shaanxi Normal University since 2008. The purpose of the conference is to share our experiences and knowledge in regard to the theory, frontier developments and researches, as well as possible applications of them in solving practical problems. A lot of current issues have been discussed, and some of them have been effectively , as the first time of the conference debut in this city, we’ll have a unique session. The topic of prepared presentations is Mathematics. Today, speakers will share their thoughts on how to effectively run models in different issues and give a reasonable ,we’ll have a Q&A session,which allows the everyone to ask some questions you may be interested. I am sure that you will find some topics to be presented both interesting and me introduce the first speaker,who is very very rich,not in dollars,but in knowledges and experiences,He got his in financial economics at the UCB,followed by a series of teaching and research positions at MIT and Harvard. Please dont hesitate to join me in welcoming our first speaker, , whose topic is entitled threshold effect between the scale of shadow banking and the stability of the banking system. Welcome.。
学术报告会开场白和结束语 第3篇
英文版医学学术报告发言稿Ladies and gentlemen,Good morning! I am honored to stand here today and present my research findings on the topic of _The Role of Genetics in Cancer Development and Treatment_. Over the past few years, there have been significant advancements in our understanding of the intricate relationship between genetics and cancer, leading to new possibilities for personalized treatment approaches. My goal today is to share with you the latest research in this field and discuss its implications for both clinical practice and future , it is essential to acknowledge that cancer is a complex disease caused by a combination of genetic and environmental factors. While environmental factors such as exposure to carcinogens, lifestyle choices, and infections play a significant role in cancer development, it is becoming increasingly evident that genetic alterations also contribute to the initiation and progression of various types of discovery of oncogenes and tumor suppressor genes has revolutionized our understanding of cancer genetics. Oncogenes are genes that have the potential to cause cancer when they are mutated or activated, promoting cell growth and division. On the other hand, tumor suppressor genes are responsible for regulating cell growth and division, and when these genes are mutated or inactivated, they lose their ability to control cell proliferation, leading to uncontrolled cell growth and the development of cancer. Mutations in these genes can be inherited or acquired during a person's lifetime, and they can significantly increase the risk ofdeveloping certain types of remarkable breakthrough in cancer genetics is the identification of specific genetic mutations that are strongly associated with particular types of cancer. For example, mutations in the BRCA1 and BRCA2 genes are strongly associated with an increased risk of developing breast and ovarian cancer. Genetic testing for these mutations has become an essential tool in identifying individuals at high risk, enabling healthcare providers to offer targeted surveillance and preventive measures. Additionally, the discovery of these mutations has paved the way for the development of novel treatment modalities, such as PARP inhibitors, which specifically target cancer cells with BRCA recent years, next-generation sequencing technologies have allowed for the comprehensive analysis of the entire cancer genome, leading to the discovery of numerous additional genetic alterations implicated in cancer development. These discoveries have opened up new avenues for personalized treatment approaches, as they can help identify specific genetic alterations that drive individual tumors. Targeted therapies, such as tyrosine kinase inhibitors and immune checkpoint inhibitors, have demonstrated remarkable efficacy in specific subsets of patients with certain genetic alterations. For example, the use of tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations has shown improved outcomes compared to traditional chemotherapy approaches. Furthermore, advances in our understanding of tumorheterogeneity have shed light on the challenges in cancer treatment and the development of drug resistance. Tumors are composed of a heterogeneous population of cells with different genetic alterations, making them resilient and adaptable to treatment. The emergence of drug-resistant clones within a tumor, as a result of further genetic alterations, poses a significant challenge to the effectiveness of targeted therapies. Efforts to overcome drug resistance involve the development of combination therapies, immune-based approaches, and the use of novel technologies such as liquid biopsies, which can detect minimal residual disease and monitor treatment conclusion, the field of cancer genetics has made tremendous strides in recent years, revolutionizing our understanding of cancer biology and treatment approaches. The identification of specific genetic alterations, the advent of next-generation sequencing technologies, and the development of targeted therapies have paved the way for personalized medicine and improved patient outcomes. However, numerous challenges, such as tumor heterogeneity and drug resistance, still need to be addressed. Continued research efforts in the field of cancer genetics will not only deepen our understanding of the disease but also open up new opportunities for innovative therapeutic you for your attention. I would be happy to answer any questions you may have.。
学术报告会开场白和结束语 第4篇
学术英文演讲稿开场白学术英文演讲稿开场白现在，国家和个人的经济实力越来越强，科研项目的资助力度也越来越大。
因此，在国内和去海外，进行学术访问和交流也就越来越多和平凡了。
越来越多的中国专家、教授和学者在国际会议上，同国际同行们同台，用英文探讨科技学术发展和前沿问题和成果。
直接用英文在国际学术大会上演讲和报告，的确是一个大力宣传我们自己科技创新成果的最佳方法。
由于英文是我们的第二语文，同时中英文化、思维和生活存在相当大的差别，我们用英文做科技学术演讲的实际效果，有时还不理想。
有时难以让不懂中文思维方式的人们，理解和体会的报告内容和意思。
这样，他们会对我们创新成果失去兴趣，或不认同我们创新成果。
如果这样，我们的学术报告也就没有达到希望的效果。
因此，我们用英文做学术报告一定要让仅懂英文的人听明白、能理解和体会的报告内容和思想。
要让他们感兴趣、进一步地认同我们的创新成果，在将来引用我们的创新成果。
如果这样，我们的英文学术演讲也就达到应有的效果。
特别地，他们知道英文不是我们的第一语文(native English speaker)。
如果他们能从我们的英文报告中，学到有价值的东西，他们应该是可以被感动的、是会承认和接受我们的创新成果的。
以下是我多年做学术报告的几点体会和技巧。
正是由于人们都知道英文不是我们的第一语文，因此，我们在用英文做学术演讲和报告时，我们要大声清楚地说英文每一个单字，要理直气壮，不要害怕自己说错了英文。
要多用简单句、少用复合句。
要将重点词汇加重发音。
要让他人感到你对演讲课题十分感兴趣!其次，我们要精心制作每张多媒体ppt图片，让听众可听可视。
我们要将自己的一个科技创新问题、过程、结果和结论划分成细小单元和步骤流程。
用精心制作的ppt，通过图像和简单讲解来动态地、一步一印地演讲它们，并及时附上相应的英文专业词汇和单词。
这样，听众可眼视投影屏幕上演示的图像和英文词汇。
再通过耳听英文讲解来跟上内容，在脑海中产生正确的形象思维和过程。